Stay with Moneycontrol to get real time updates on NIFTY MIDCAP 150 share price, top gainers, top losers and market insights.

This is eligible for 180 days of generic drug exclusivity. The company will manufacture the product at its facility situated in India.

Indian drugmaker Lupin Ltd. has announced that it spinned off its consumer healthcare business with effect from July 1. The newly formed wholly owned subsidiary will be called as LupinLife Consumer ...

Lupin has launched Prucalopride tablets in the US following USFDA approval. The bowel disorder treatment enters a $184 million market and will be manufactured at the company's Goa facility.

Lupin launches generic Prucalopride tablets for chronic idiopathic constipation in the US market, a bioequivalent to Takeda's Motegrity, with estimated annual sales of USD 184 million.

Lupin gets USFDA nod for new constipation drug, stock gains This product, bioequivalent to Motegrity Tablets of Takeda Pharmaceuticals, will be manufactured at Lupin's Goa facility in India.

Drugmaker Lupin Ltd. informed the exchanges that it has received approval from the United States Food & Drug Regulator (USFDA) for a drug, which is used in the treatment of Chronic Idiopathic ...

Wide Open Agriculture aims to elevate lupin as a first choice protein A Western-Australian agribusiness is aiming to elevate lupins as a major source of protein for human consumption, but ...

Lupin has signed a license and supply agreement with Sino Universal Pharmaceuticals for the commercialization of tiotropium dry powder inhaler, 18 mcg/capsule, in the Chinese market, for the ...

Indian Stocks Under Pressure Amid Israel-Iran Tension: Adani Port, TCS, Wipro, Infosys, LT, SBI Shares Falling ...